Cedrik M. Britten

Chief Tech/Sci/R&D Officer bei IMMATICS N.V.

Vermögen: 2 Mio $ am 30.04.2024

49 Jahre

Health Technology

Consumer Services

Aktive Positionen von Cedrik M. Britten

Unternehmen	Position	Beginn	Ende
IMMATICS N.V.	Chief Tech/Sci/R&D Officer	01.06.2020	-
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Chief Tech/Sci/R&D Officer	01.06.2020	-

Unternehmen	Position	Beginn	Ende
GSK PLC	Corporate Officer/Principal	01.02.2015	01.05.2020
BioNTech RNA Pharmaceuticals GmbH BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany.	Chief Tech/Sci/R&D Officer	01.06.2010	01.01.2015

The Johannes Gutenberg University of Mainz

Doctorate Degree

International

Deutschland	5
Vereinigtes Königreich	2

Operativ

Chief Tech/Sci/R&D Officer	3
Corporate Officer/Principal	1
Doctorate Degree	1

Sektoral

Health Technology	5
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
GSK PLC	Health Technology
IMMATICS N.V.	Health Technology

Private Unternehmen	2
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Health Technology
BioNTech RNA Pharmaceuticals GmbH BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany.	Health Technology

Private Unternehmen

Health Technology